Janney Montgomery Scott LLC Sells 410 Shares of Insulet Co. (NASDAQ:PODD)

Janney Montgomery Scott LLC lessened its stake in shares of Insulet Co. (NASDAQ:PODD) by 7.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,251 shares of the medical instruments supplier’s stock after selling 410 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Insulet were worth $1,371,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PODD. Blue Trust Inc. increased its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares during the period. Venturi Wealth Management LLC boosted its holdings in Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares in the last quarter. TD Private Client Wealth LLC lifted its holdings in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial bought a new stake in shares of Insulet during the fourth quarter worth about $57,000. Finally, Versant Capital Management Inc increased its holdings in Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock worth $80,000 after purchasing an additional 157 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PODD. Citigroup raised their price target on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. TD Cowen raised their price target on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Canaccord Genuity Group boosted their price target on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Morgan Stanley raised their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Finally, Barclays boosted their target price on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $272.81.

Insulet Stock Up 0.2 %

Shares of NASDAQ PODD opened at $278.90 on Tuesday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The business has a 50-day moving average of $268.94 and a 200-day moving average of $239.09. The firm has a market capitalization of $19.56 billion, a price-to-earnings ratio of 47.76, a PEG ratio of 3.49 and a beta of 1.23. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $286.39.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The firm had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. During the same quarter in the prior year, the firm earned $0.71 EPS. Sell-side analysts expect that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.